Michael Singer - 13 Nov 2023 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Director, 10%+ Owner
Signature
/s/ Michael Singer
Issuer symbol
RNAC
Transactions as of
13 Nov 2023
Net transactions value
$0
Form type
4
Filing time
15 Nov 2023, 16:41:44 UTC
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SELB Common Stock Award $0 +110,123 $0.000000 110,123 13 Nov 2023 Direct F1
transaction SELB Common Stock Other $0 +197,663 $0.000000 197,663 13 Nov 2023 by trust F1, F2
transaction SELB Common Stock Other $0 +29,212 $0.000000 29,212 13 Nov 2023 by trust F1, F3
transaction SELB Common Stock Other $0 +3,670 $0.000000 3,670 13 Nov 2023 by trust F1, F4
transaction SELB Common Stock Other $0 +49,555 $0.000000 49,555 13 Nov 2023 as custodian F1, F5
transaction SELB Common Stock Other $0 +49,555 $0.000000 49,555 13 Nov 2023 as custodian F1, F6
transaction SELB Common Stock Other $0 +7,616 $0.000000 7,616 13 Nov 2023 by spouse F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SELB Series A Non-Voting Convertible Preferred Stock Award +6,305 6,305 13 Nov 2023 Common Stock 6,304,559 Direct F1, F8
transaction SELB Series A Non-Voting Convertible Preferred Stock Other +11,316 11,316 13 Nov 2023 Common Stock 11,316,263 by trust F1, F2, F8
transaction SELB Series A Non-Voting Convertible Preferred Stock Other +1,672 1,672 13 Nov 2023 Common Stock 1,672,389 by trust F1, F3, F8
transaction SELB Series A Non-Voting Convertible Preferred Stock Other +210 210 13 Nov 2023 Common Stock 210,152 by trust F1, F4, F8
transaction SELB Series A Non-Voting Convertible Preferred Stock Other +2,837 2,837 13 Nov 2023 Common Stock 2,837,052 as custodian F1, F5, F8
transaction SELB Series A Non-Voting Convertible Preferred Stock Other +2,837 2,837 13 Nov 2023 Common Stock 2,837,052 as custodian F1, F6, F8
transaction SELB Series A Non-Voting Convertible Preferred Stock Other +436 436 13 Nov 2023 Common Stock 436,066 by spouse F1, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger.
F2 Shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust.
F3 Shares are held in a trust for which the reporting person is a beneficiary. The reporting person is a trustee of the trust.
F4 Shares are held in a trust for which the reporting person is a beneficiary. The reporting person's spouse is a trustee of the trust.
F5 The shares are held for LS, the child of the reporting person, through a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA") for which the reporting person serves as custodian.
F6 The shares are held for SS, the child of the reporting person, through a custodial account established pursuant to the UTMA for which the reporting person serves as custodian.
F7 Shares are held by the reporting person's spouse.
F8 Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.